PARG-IN-4

CAT: 0804-HY-156881-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-156881-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PARG-IN-4 (Formula (A) ) is an orally available PARG inhibitor (EC50=1.9 nM) with cell membrane permeability. PARG-IN-4 can effectively inhibit tumor growth in mouse models. PARG-IN-4 can be used in cancer research[1].
CAS Number
[2988890-20-4]
UNSPSC
12352005
Target
Apoptosis; Poly (ADP-ribose) Glycohydrolase (PARG)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/parg-in-4.html
Purity
98.86
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
CC1(CC1)NS(=O)(C2=CC(N3C[C@@H](N[C@H](C3)C)C)=C(C=NN4C5=NN=C(C(F)F)S5)C4=C2)=O
Molecular Formula
C20H25F2N7O2S2
Molecular Weight
497.59
References & Citations
[1]Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 4

Related Products

CatalogName
HY-171789PARG-IN-7
HY-P88169PARG Antibody (YA7853, Mouse)
HY-RS10042Parg Rat Pre-designed siRNA Set A
HY-RS10041Parg Mouse Pre-designed siRNA Set A
HY-RS10040PARG Human Pre-designed siRNA Set A
HY-153590-01PARP-1-IN-4
HY-162409PAR4 antagonist 4
HY-170054-01Para-fluoro 4-ANBP
HY-P1313APAR 4 (1-6) (TFA)
HY-P1309-01PAR-4 Agonist Peptide, amide

Alternative Products

CatalogName
MBS5823198PARG-IN-4
MBS8535413-01PARG
TS408530P5PARG CytoSection
YF-PA15667anti-PARG
571466-01PARG (FITC)
OACA10603-100UGPARG Antibody
B2022080PARG (Human)
DF13517-BPPARG Peptide
MF-0119162-01PARG-IN-7
571465-01PARG (Biotin)

Popular Products